Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Doxycycline added to targeted therapy for metastatic lung adenocarcinoma
ACTRN12625000697482Phase 2Recruiting
- Sponsor
- University of Technology Sydney
- Start
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Non-small cell lung cancer adenocarcinoma (NSCLC) comparing Doxycycline + standard targeted therapy with Placebo + standard targeted therapy (2 arms). Primary endpoint: Efficacy of doxycycline versus placebo with standard of care. Started Mar 2026; status: recruiting.
02
Drugs
doxycycline
03
Conditions
Non-small cell lung cancer adenocarcinoma (NSCLC)
Beyond the preview
Go deeper on ACTRN12625000697482.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12625000697482.